As­traZeneca cuts Alex­ion's PhI­II Wil­son dis­ease drug, takes $244M write­down

As­traZeneca is call­ing it quits with a Phase III rare dis­ease pro­gram it ob­tained via the $39 bil­lion ac­qui­si­tion of Alex­ion.

ALXN1840, or bis-choline tetrathiomolyb­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER